Dose-escalated radiation does not benefit patients with low-risk prostate cancer
the ONA take:
According to a new study published online ahead of print this week in JAMA Oncology, researchers have found that higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer. However, this association was not observed in patients with low-risk disease.
For the study, researchers analyzed data from 42,481 men with prostate cancer included in the National Cancer Database. Of those, 12,229 had low-risk disease, 16,714 had intermediate-risk disease, and 13,538 had high-risk prostate cancer. Patients were all diagnosed between 2004 and 2006 and received either standard-dose external-beam radiation therapy or dose-escalated radiation.
Results showed that higher dose radiotherapy was associated with increased survival in those with intermediate- and high-risk disease, but not in those with low-risk disease. The findings suggest that aggressive radiotherapy may not be beneficial in men with low-risk prostate cancer, adding to the evidence that watchful waiting or active surveillance may be better for these patients.
Higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|